Ranbaxy Laboratories, Inc.

Lupin, Inc.

Sun Pharmaceutical Industries Limited

Other

Sudershan Kumar Arora

Jang Bahadur Gupta

Rajender Kumar Kamboj

Mohan Prasad

Neelima Sinha

Rakesh Kumar Sinha

Anita Mehta

Shankar Ajay

Nawal Kishore

Vishwas D Joshi

Sanjay Kumar Jain

Vinod Kumar Arora

Prathap Sreedharan Nair

Gourhari Jana

Ashok Rattan

Bruhaspathy Miriyala

Jyoti Srivastava

Ram Shankar Upadhayaya

Rajinder K Jalali

Neeta Gupta

Simrata Bedi

Sanjay Kumar Sharma

Manisha Pandya

Vyas M Shingatgeri

Jaiprakash Jaysingrao Bhelonde

Monika Obrah

Vijaykumar Jagdishwar Patil

Abhijit Ray

Anil Kashiram Hajare

Arundutt Viswanatham Silamkoti

Ashwani Kumar Verma

Biswajit Das

Sonali Rudra

Majid Bashir Sayyed

Nitin Maheshwari

Jasbir Singh Arora

Rajan Goel

Prasad Purushottam Dixit

Vandita Srivastava

Sameer Shankar Walunj

Ram Shankar Upadhyaya

Boju Srinivasulu

Roshan Ramesh Medhane

Bireshwar Mukherjee

Jang P Gupta

Madan P Tanwar

Geeta Sharma

Sai Kumar Chakka

Azmi Reddy

Pravin Patil

K H Sreedhara Swamy

The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Topical pharmaceutical composition comprising nanonized silver sulfadiazine

The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.

Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors

Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains ofas well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

Pyrrole derivatives as antimycobacterial compounds

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as-intracellular complex,and. The compound and its pharmaceutically acceptable salts act as antibacterial agents. Also mentioned is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as, drug resistant-intracellular complex,and., including administering an antimycobacterially effective amount of the compound and/or pharmaceutically acceptable salts. There is also mentioned a process for the manufacture of the compound or its pharmaceutically acceptable salts.

Antimycobacterial compounds

A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems ofplant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems ofplant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-&#x3b3; inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders

This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists

An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.

Antimycobacterial pharmaceutical composition

This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists

This invention relates generally to compounds and processes for synthesizing derivatives of 2-3--isopropylidene-&#x3b1;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3--isopropylidene-&#x3b1;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.

Derivatives of monosaccharides as cell adhesion inhibitors

This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&#x3b1;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&#x3b1;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.

The present invention relates to certain substituted phenyl piperazinyl oxazolidinones, for example, to those having the structure of Formula Iwith the variables as defined within, and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such asspp. andspp. species, and acid fast organisms such asandspp.

Oxazolidinone piperazinyl derivatives as potential antimicrobials

The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.

Azole compounds as therapeutic agents for fungal infections

Growing community of inventors

Gurgaon, India

Sudershan Kumar Arora